Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 4/2013

01-04-2013 | Research Paper

The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review

Authors: A. A. P. Slesser, P. Georgiou, G. Brown, S. Mudan, R. Goldin, P. Tekkis

Published in: Clinical & Experimental Metastasis | Issue 4/2013

Login to get access

Abstract

Forty to fifty percent of colorectal cancer (CRC) patients develop colorectal liver metastases (CLM) that are either synchronous or metachronous in presentation. Clarifying whether there is a biological difference between the two groups of liver metastases or their primaries could have important clinical implications. A systematic review was performed using the following resources: MEDLINE from PubMed (1950 to present), Embase, Cochrane and the Web of Knowledge. Thirty-one articles met the inclusion criteria. The review demonstrated that the majority of studies found differences in molecular marker expression between colorectal liver metastases and their respective primaries in both the synchronous and metachronous groups. Studies investigating genetic aberrations demonstrated that the majority of changes in the primary tumour were ‘maintained’ in the colorectal liver metastases. A limited number of studies compared the primary tumours of the synchronous and metachronous groups and generally demonstrated no differences in marker expression. Although there were conflicting results, the colorectal liver metastases in the synchronous and metachronous groups demonstrated some differences in keeping with a more aggressive tumour subtype in the synchronous group. This review suggests that biological differences may exist between the liver metastases of the synchronous and metachronous groups. Whether there are biological differences between the primaries of the synchronous and metachronous groups remains undetermined due to the limited number of studies available. Future research is required to determine whether differences exist between the two groups and should include comparisons of the primary tumours.
Literature
1.
2.
Bruin SC, He Y et al (2011) Molecular alterations associated with liver metastases development in colorectal cancer patients. Br J Cancer 105(2):281–287PubMedCrossRef
3.
Thomas P, Forse RA, Bajenova O (2011) Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clin Exp Metastasis 28(8):923–932PubMedCrossRef
4.
Bird NC, Mangnall D, Majeed AW (2006) Biology of colorectal liver metastases: a review. J Surg Oncol 94(1):68–80PubMedCrossRef
5.
Tan EK, Ooi LL(2010) Colorectal cancer liver metastases–understanding the differences in the management of synchronous and metachronous disease. Ann Acad Med Singapore 39(9):719-33
6.
7.
Ghadjar P, Rubie C, Aebersold DM, Keilholz U (2009) The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer 125(4):741–745PubMedCrossRef
8.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual (7th ed). Springer, New York
9.
Mekenkamp LJ, Koopman M, Teerenstra S, van Krieken JH, Mol L, Nagtegaal ID, Punt CJ (2010) Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 103(2):159–164PubMedCrossRef
10.
Dexiang Z, Li R, Ye W, Haifu W, Yunshi Z, Qinghai Y, Shenyong Z, Bo X, Li L, Xiangou P, Haohao L, Lechi Y, Tianshu L, Jia F, Xinyu Q, Jianmin X (2012) Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases. Ann Surg Oncol 19(9):2860–2868PubMedCrossRef
11.
Mantke R, Schmidt U, Wolff S, Kube R, Lippert H (2012) Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicentre observational study. Eur J Surg Oncol 38(3):259–265PubMedCrossRef
12.
13.
Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, Moschetti I, Phillips B, Thornton H, Goddard O, Hodgkinson M. “The Oxford 2011 Levels of Evidence”. Oxford Centre for Evidence-Based Medicine. http://​www.​cebm.​net/​index.​aspx?​o=​5653. Accessed 23 Jan 2012
14.
Swan PJ, Welsh FK, Chandrakumaran K, Rees M (2011) Long-term survival following delayed presentation and resection of colorectal liver metastases. Br J Surg 98(9):1309–1317. doi:10.​1002/​bjs.​7527. PubMedCrossRef
15.
Wang SC, Lin JK, Wang HS, Yang SH, Li AF, Chang SC (2010) Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis 25(10):1185–1191PubMedCrossRef
16.
Rudmik LR, Magliocco AM (2005) Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 92(4):347–359PubMedCrossRef
17.
Li JQ, Miki H, Wu F, Saoo K, Nishioka M, Ohmori M, Imaida K (2002) Cyclin A correlates with carcinogenesis and metastasis, and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms. Hum Pathol 33(10):1006–1015PubMedCrossRef
18.
Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M (1998) Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 153(3):681–687PubMedCrossRef
19.
Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154(2):313–323PubMedCrossRef
20.
Li JQ, Miki H, Ohmori M, Wu F, Funamoto Y (2001) Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum Pathol 32(9):945–953PubMedCrossRef
21.
Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV (2008) Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. Int J Oncol 33(6):1257–1262PubMed
22.
Inokuchi M, Uetake H, Shirota Y, Yamada H, Tajima M, Sugihara K (2004) Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. Cancer Chemother Pharmacol 53(5):391–396PubMedCrossRef
23.
Ghadjar P, Coupland SE, Na IK, Noutsias M, Letsch A, Stroux A, Bauer S, Buhr HJ, Thiel E, Scheibenbogen C, Keilholz U (2006) Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 24(12):1910–1916PubMedCrossRef
24.
Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS (2005) Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23(12):2744–2753PubMedCrossRef
25.
Ghadjar P, Rubie C, Aebersold DM, Keilholz U (2009) The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer 125(4):741–745PubMedCrossRef
26.
Wu Y, Jin M, Xu H, Shimin Z, He S, Wang L, Zhang Y (2010) Clinicopathologic significance of HIF-1α, CXCR4, and VEGF expression in colon cancer. Clin Dev Immunol Epub 2010 Oct 7
27.
Kim YW, Ko YT, Kim NK, Chung HC, Min BS, Lee KY, Park JP, Kim H (2010) A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: the significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis. Scand J Gastroenterol 45(2):217–225PubMedCrossRef
28.
Esposito DL, Aru F, Lattanzio R, Morgano A, Abbondanza M, Malekzadeh R, Bishehsari F, Valanzano R, Russo A, Piantelli M, Moschetta A, Lotti LV, Mariani-Costantini R (2012) The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer. PLoS One 7(4):e36190PubMedCrossRef
29.
Bommer GT, Feng Y, Iura A, Giordano TJ, Kuick R, Kadikoy H, Sikorski D, Wu R, Cho KR (2010) Fearon ER.IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype. J Biol Chem 285(3):1928–1938PubMedCrossRef
30.
Ayaki M, Komatsu K, Mukai M, Murata K, Kameyama M, Ishiguro S, Miyoshi J, Tatsuta M, Nakamura H (2001) Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colorectal adenocarcinomas. Clin Cancer Res 7(10):3106–3112PubMed
31.
Kuramochi H, Nakajima G, Kaneko Y, Nakamura A, Inoue Y, Yamamoto M, Hayashi K (2012) Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. BMC Cancer 13(12):88CrossRef
32.
Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi ZA (2006) Signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38(9):1043–1048PubMedCrossRef
33.
Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, Kabeshima Y, Yorozuya K, Yamamoto K, Mukai M, Kitajima M (2002) Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 45(1):98–103PubMedCrossRef
34.
Watanabe T, Kobunai T, Yamamoto Y, Kanazawa T, Konishi T, Tanaka T, Matsuda K, Ishihara S, Nozawa K, Eshima K, Muto T, Nagawa H (2010) Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. Eur J Cancer 46(11):2119–2126PubMedCrossRef
35.
Nakamoto RH, Uetake H, Iida S, Kolev YV, Soumaoro LT, Takagi Y, Yasuno M, Sugihara K (2007) Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn J Clin Oncol 37(9):679–685PubMedCrossRef
36.
Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD, Biasco G (2008) Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 99(10):1729–1734PubMedCrossRef
37.
Prabhudesai SG, Rekhraj S, Roberts G, Darzi AW, Ziprin P (2007) Apoptosis and chemo-resistance in colorectal cancer. J Surg Oncol 96(1):77–88 ReviewPubMedCrossRef
38.
Yarom N, Jonker DJ (2011) The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med 11(57):95–105PubMed
39.
De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ, De Vries EG (1998) Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 28(4):971–979PubMedCrossRef
40.
Kito A, Tanaka K, Fujimaki H, Nakazawa M, Togo S, Minami M, Shimada H (2007) Tumor doubling time and local immune response hepatic metastases from colorectal cancer. J Surg Oncol 96(6):525–533PubMedCrossRef
41.
Miyagawa S, Soeda J, Takagi S, Miwa S, Ichikawa E, Noike T (2004) Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol 35(11):1392–1396PubMedCrossRef
42.
van der Wal GE, Gouw AS, Kamps JA, Moorlag HE, Bulthuis ML, Molema G, de Jong KP (2012) Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. Ann Surg 255(1):86–94PubMedCrossRef
43.
Shirota Y, Ichikawa W, Uetake H, Yamada H, Nihei Z, Sugihara K (2002) Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. Ann Surg Oncol 9(6):599–603PubMedCrossRef
44.
Shi H, Hood KA, Hayes MT, Stubbs RS (2011) Proteomic analysis of advanced colorectal cancer by laser capture microdissection and two-dimensional difference gel electrophoresis. J Proteomics 75(2):339–351PubMedCrossRef
45.
D’Arrigo A, Belluco C, Ambrosi A, Digito M, Esposito G, Bertola A, Fabris M, Nofrate V, Mammano E, Leon A, Nitti D, Lise M (2005) Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer 115(2):256–262PubMedCrossRef
46.
Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92(5):1331–1346PubMedCrossRef
47.
Al-Mulla F, Keith WN, Pickford IR, Going JJ, Birnie GD (1999) Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer 24(4):306–314PubMedCrossRef
48.
Takahashi Y, Ishii Y, Nishida Y, Ikarashi M, Nagata T, Nakamura T, Yamamori S, Asai S (2006) Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH. Cancer Genet Cytogenet 168(1):30–35PubMedCrossRef
49.
Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallböhmer D, Park S, Danenberg KD, Takasaki K, Danenberg PV (2006) Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 12(1):29–33PubMedCrossRef
50.
Ono M, Sakamoto M, Ino Y, Moriya Y, Sugihara K, Muto T, Hirohashi S (1996) Cancer cell morphology at the invasive front and expression of cell adhesion-related carbohydrate in the primary lesion of patients with colorectal carcinoma with liver metastasis. Cancer 78(6):1179–1186PubMedCrossRef
51.
Nanashima A, Yamaguchi H, Yasutake T, Sawai T, Kusano H, Tagawa Y, Nakagoe T, Ayabe H (1997) Gain of chromosome 20 is a frequent aberration in liver metastasis of colorectal cancers. Dig Dis Sci 42(7):1388–1393PubMedCrossRef
52.
Kitabatake T, Kojima K, Fukasawa M, Beppu T, Futagawa S (2002) Correlation of thymidine phosphorylase staining and the Ki-67 labeling index to clinicopathologic factors and hepatic metastasis in patients with colorectal cancer. Surg Today 32(4):322–328PubMedCrossRef
53.
Konishi K, Watanabe Y, Shen L, Guo Y, Castoro RJ, Kondo K, Chung W, Ahmed S, Jelinek J, Boumber YA, Estecio MR, Maegawa S, Kondo Y, Itoh F, Imawari M, Hamilton SR, Issa JP (2011) DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PLoS One 6(11):e27889PubMedCrossRef
54.
Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Köhne CH, Hillebrand T, Daniel PT, Fong Y, Lorenz M (2001) Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 27(1):80–87PubMedCrossRef
55.
Chen J, Li Q, Wang C, Wu J, Zhao G (2010) Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases. Ann Surg Oncol 17(6):1555–1563PubMedCrossRef
56.
Kochhar R, Halling KC, McDonnell S, Schaid DJ, French AJ, O’Connell MJ, Nagorney DM, Thibodeau SN (1997) Allelic imbalance and microsatellite instability in resected Duke’s D colorectal cancer. Diagn Mol Pathol 6(2):78–84PubMedCrossRef
57.
Nanashima A, Shibata K, Nakayama T, Tobinaga S, Araki M, Kunizaki M, Takeshita H, Hidaka S, Sawai T, Nagayasu T, Yasutake T (2009) Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma. Ann Surg Oncol 16(8):2130–2137PubMedCrossRef
58.
Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, Brand K, Steinert G, Schneider M, Mollenhauer M, Reissfelder C, Klupp F, Fritzmann J, Wunder C, Benner A, Kloor M, Huth C, Contin P, Ulrich A, Koch M, Weitz J (2011) Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 17(24):7654–7663PubMedCrossRef
Metadata
Title
The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review
Authors
A. A. P. Slesser
P. Georgiou
G. Brown
S. Mudan
R. Goldin
P. Tekkis
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 4/2013
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-012-9551-8

Other articles of this Issue 4/2013

Clinical & Experimental Metastasis 4/2013 Go to the issue

Research Paper

Integrin α3β1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization

Research Paper

Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus

Research Paper

Increased LDH5 expression is associated with lymph node metastasis and outcome in oral squamous cell carcinoma

Research Paper

Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer

Research Paper

Smad interacting protein 1 (SIP1) is associated with peritoneal carcinomatosis in intestinal type gastric cancer

Research Paper

Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear β-catenin in cerebral metastasis of lung adenocarcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits